Search

Contributor:

Genentech, Inc.

AMD/DME Case Files: Real-World Patient Profiles

ARCHWAY at AAO

New Retina Radio Journal Club: Phase 2 LADDER Study Data

AAO Late Breaker: Ang-2 Mediation in DME Therapy

The Art of Drug Choice: Wet AMD Pipeline

Faricimab in Phase 2 and 3

ASRS 2021: ARCHWAY and TENAYA/LUCERNE

Diabetic Eye Disease: What's Next for Your Patients?

New Retina Radio Journal Club: Phase 2 LADDER Study Data

Aleksandra Rachitskaya, MD; Mrinali Gupta, MD; Eric Nudleman, MD, PhD; and Aris Thanos, MD

The Art of Drug Choice: International Panel in Wet AMD: Phase 3 and Real-World Data to Watch

Diabetic Eye Disease: What's Next for Your Patients?

Rishi Singh, MD; and Nathan Steinle, MD

Diabetic TRD

Diabetic TRD

Dimitra Skondra, MD, PhD

ASSESS Study - 24 Months

ASSESS Study - 24 Months

Rishi P. Singh, MD

Abicipar Pegol in Phase 2

Abicipar Pegol in Phase 2

Pravin Dugel, MD

Trials on Steroids for Diabetic Eye Disease

Trials on Steroids for Diabetic Eye Disease

Albert J. Augustin, MD

Three Exciting New Drugs

Three Exciting New Drugs

Pravin U. Dugel, MD

Anti-VEGF Therapy and Vitrectomy in Severe PDR

Anti-VEGF Therapy and Vitrectomy in Severe PDR

Anti-VEGF for Radiation Retinopathy

Anti-VEGF for Radiation Retinopathy

Amy C. Schefler, MD

TRUCKEE Study Data

TRUCKEE Study Data

Ramin Tadayoni, MD, PhD and Arshad Khanani, MD, MA

Highlights From the Phase 3 Chroma and Spectri Trials

Highlights From the Phase 3 Chroma and Spectri Trials

Carl D. Regillo, MD, FACS

The Clinical Benefits of the PDS

The Clinical Benefits of the PDS

Patricia Udaondo, MD